Cadrofloxacin HCl | CAS# 128427-55-4 (HCl) | bacterial infections

MedKoo Cat#: 413362 | Name: Cadrofloxacin HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cadrofloxacin HCl was studied for the treatment of bacterial infections.

Chemical Structure

Cadrofloxacin HCl

CAS#128427-55-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 413362

Name: Cadrofloxacin HCl

CAS#: 128427-55-4 (HCl)

Chemical Formula: C19H21ClF3N3O4

Exact Mass: 447.1170

Molecular Weight: 447.84

Elemental Analysis: C, 50.96; H, 4.73; Cl, 7.92; F, 12.73; N, 9.38; O, 14.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

128427-55-4 (HCl) 153808-85-6 (free base)

Synonym

Cadrofloxacin HCl; CS940; CS 940; CS-940

IUPAC/Chemical Name

3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-1,4-dihydro-7-((3S)-3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride

InChi Key

AWPMTCKEQGUMTG-FVGYRXGTSA-N

InChi Code

InChI=1S/C19H20F3N3O4.ClH/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28;/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28);1H/t9-;/m0./s1

SMILES Code

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@H](C)NCC4)=C3OC(F)F)C1=O)O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 447.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ma RL, Zhou HH, Liu R, Wang EH, Sheng LS. [Analysis of impurity in caderofloxacin]. Yao Xue Xue Bao. 2003 Dec;38(12):950-2. Chinese. PubMed PMID: 15040093. 2: Kawahara S, Tada A, Nagare H. [Clinical evaluation of new quinolones as antituberculosis drugs]. Kekkaku. 1999 Jan;74(1):71-5. Review. Japanese. PubMed PMID: 10067058. 3: Namba K. [View of development of fluoroquinolones]. Kekkaku. 1999 Jan;74(1):47-52. Review. Japanese. PubMed PMID: 10067055. 4: Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Review. Japanese. PubMed PMID: 9883617. 5: Miyazaki S, Domon H, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N, Yamaguchi K. In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections. Antimicrob Agents Chemother. 1997 Nov;41(11):2582-5. PubMed PMID: 9371375; PubMed Central PMCID: PMC164170. 6: Schmitz FJ, Jones ME. Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? Int J Antimicrob Agents. 1997 Jun;9(1):1-19. PubMed PMID: 18611815. 7: Mizutani S. [Chemotherapy of pulmonary Mycobacterium kansasii infection]. Kekkaku. 1996 Sep;71(9):527-31. Japanese. PubMed PMID: 8914388. 8: Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya S. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug;40(8):1835-42. PubMed PMID: 8843290; PubMed Central PMCID: PMC163426. 9: Yamane N, Chilima BZ, Tosaka M, Okazawa Y, Tanno K. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media]. Kekkaku. 1996 Aug;71(8):453-8. Japanese. PubMed PMID: 8831190. 10: Masuda N, Takahashi Y, Otsuki M, Ibuki E, Miyoshi H, Nishino T. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Antimicrob Agents Chemother. 1996 May;40(5):1201-7. PubMed PMID: 8723467; PubMed Central PMCID: PMC163292. 11: Biedenbach DJ, Sutton LD, Jones RN. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30. PubMed PMID: 8619590; PubMed Central PMCID: PMC162937.